In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020

Chang, Chih-YenChih-YenChangLee, Yu-LinYu-LinLeeYU-TSUNG HUANGKo, Wen-ChienWen-ChienKoHo, Mao-WangMao-WangHoPO-REN HSUEH2023-05-192023-05-192023-04-1309248579https://scholars.lib.ntu.edu.tw/handle/123456789/631188Antimicrobial resistance due to β-lactamase production is a worldwide issue, and β-lactamase inhibitors have been developed to overcome the growing problem. This study aimed to evaluate the in vitro activities of two recently introduced carbapenem/β-lactamase inhibitor combinations - imipenem/relebactam and meropenem/vaborbactam - and their comparators against Enterobacterales from patients with urinary tract infections (UTIs).enCarbapenem resistance; Cross-resistance; Enterobacterales; Multidrug resistance; Novel β-lactam combination agents[SDGs]SDG3In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020journal article10.1016/j.ijantimicag.2023.106815370593432-s2.0-85158035858https://api.elsevier.com/content/abstract/scopus_id/85158035858